ES2425593T3 - Emulsiones oftálmicas de aceite en agua que contienen prostaglandinas - Google Patents
Emulsiones oftálmicas de aceite en agua que contienen prostaglandinas Download PDFInfo
- Publication number
- ES2425593T3 ES2425593T3 ES08749111T ES08749111T ES2425593T3 ES 2425593 T3 ES2425593 T3 ES 2425593T3 ES 08749111 T ES08749111 T ES 08749111T ES 08749111 T ES08749111 T ES 08749111T ES 2425593 T3 ES2425593 T3 ES 2425593T3
- Authority
- ES
- Spain
- Prior art keywords
- oil
- weight
- water emulsion
- emulsion
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 78
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 29
- 229940094443 oxytocics prostaglandins Drugs 0.000 title description 12
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 239000012071 phase Substances 0.000 claims abstract description 46
- 239000008346 aqueous phase Substances 0.000 claims abstract description 37
- 239000004094 surface-active agent Substances 0.000 claims abstract description 36
- 239000007764 o/w emulsion Substances 0.000 claims abstract description 34
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 31
- 238000009472 formulation Methods 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000013543 active substance Substances 0.000 claims abstract description 15
- 239000003921 oil Substances 0.000 claims description 75
- 235000019198 oils Nutrition 0.000 claims description 74
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims description 43
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 42
- -1 fatty acid triglycerides Chemical class 0.000 claims description 34
- 229960001160 latanoprost Drugs 0.000 claims description 33
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical group CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 26
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 22
- 229920000053 polysorbate 80 Polymers 0.000 claims description 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 18
- 229920002675 Polyoxyl Polymers 0.000 claims description 17
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 17
- 239000004530 micro-emulsion Substances 0.000 claims description 17
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 17
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 16
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 15
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 13
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 13
- 229940093471 ethyl oleate Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- NMSBTWLFBGNKON-UHFFFAOYSA-N 2-(2-hexadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCO NMSBTWLFBGNKON-UHFFFAOYSA-N 0.000 claims description 12
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 10
- 229960004926 chlorobutanol Drugs 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000000845 anti-microbial effect Effects 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 238000000265 homogenisation Methods 0.000 claims description 7
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 239000007951 isotonicity adjuster Substances 0.000 claims description 6
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 206010030043 Ocular hypertension Diseases 0.000 claims description 5
- 229960002470 bimatoprost Drugs 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 229960002368 travoprost Drugs 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims description 3
- 239000003093 cationic surfactant Substances 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000005063 solubilization Methods 0.000 claims description 3
- 230000007928 solubilization Effects 0.000 claims description 3
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims description 3
- 229960004317 unoprostone Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000005192 partition Methods 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 150000002763 monocarboxylic acids Chemical class 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000126 substance Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000006196 drop Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 229940002639 xalatan Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 206010015946 Eye irritation Diseases 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 231100000013 eye irritation Toxicity 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 231100000344 non-irritating Toxicity 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 231100000750 In vitro toxicology Toxicity 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 238000003222 MTT reduction assay Methods 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 231100000950 SkinEthic RHE Toxicity 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 229940110775 latanoprost ophthalmic solution Drugs 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960004305 lodoxamide Drugs 0.000 description 1
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000936 topical exposure Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07008357 | 2007-04-24 | ||
| EP07008357A EP1985298A1 (en) | 2007-04-24 | 2007-04-24 | Ophtalmic oil-in-water emulsions containing prostaglandins |
| US94269107P | 2007-06-08 | 2007-06-08 | |
| US942691P | 2007-06-08 | ||
| PCT/EP2008/003317 WO2008128779A1 (en) | 2007-04-24 | 2008-04-24 | Ophthalmic oil-in-water emulsions containing prostaglandins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2425593T3 true ES2425593T3 (es) | 2013-10-16 |
Family
ID=38924841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08749111T Active ES2425593T3 (es) | 2007-04-24 | 2008-04-24 | Emulsiones oftálmicas de aceite en agua que contienen prostaglandinas |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8414904B2 (enExample) |
| EP (2) | EP1985298A1 (enExample) |
| JP (1) | JP5452472B2 (enExample) |
| CN (1) | CN101674804B (enExample) |
| AU (1) | AU2008240964B2 (enExample) |
| CA (1) | CA2683672C (enExample) |
| ES (1) | ES2425593T3 (enExample) |
| MX (1) | MX2009011391A (enExample) |
| NZ (1) | NZ579954A (enExample) |
| RU (1) | RU2460516C2 (enExample) |
| WO (1) | WO2008128779A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1985298A1 (en) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| FR2934955B1 (fr) * | 2008-08-14 | 2011-07-08 | Commissariat Energie Atomique | Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions |
| FR2934954B1 (fr) | 2008-08-14 | 2011-07-22 | Commissariat Energie Atomique | Emulsion fluorescente de vert d'indocyanine |
| FR2938757B1 (fr) * | 2008-11-27 | 2010-12-31 | Octalia Technologies | Vehicule sous forme d'une emulsion huile-dans-eau notamment destine a une utilisation cosmetique ou dermatologique |
| EP2228058A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| DE102009021372A1 (de) | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
| US20100305046A1 (en) | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
| AU2014250656B2 (en) * | 2009-06-02 | 2016-05-05 | Johnson & Johnson Surgical Vision, Inc. | Omega-3 oil containing ophthalmic emulsions |
| US20100303915A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Therapeutic opthalmic emulsions |
| US9480645B2 (en) | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
| EP3421030A1 (en) * | 2009-11-09 | 2019-01-02 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| DE102011108948A1 (de) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen |
| US9278132B2 (en) * | 2012-02-13 | 2016-03-08 | Bausch & Lomb Incorporated | Ophthalmic pharmaceutical compositions and methods of making and using same |
| EP2664329A1 (de) * | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Ophthalmologisches Vehikelsystem |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| AU2016226224B2 (en) * | 2015-03-05 | 2021-07-08 | Allergan, Inc. | Self-emulsifying drug delivery system (SEDDS) for ophthalmic drug delivery |
| KR101848124B1 (ko) * | 2015-03-31 | 2018-04-11 | 단국대학교 천안캠퍼스 산학협력단 | 타크로리무스의 경구용 과포화성 마이크로에멀젼 조성물 |
| CN105748415B (zh) * | 2016-03-18 | 2019-05-07 | 上海方予健康医药科技有限公司 | 一种前列地尔冻干微乳组合物及其制备方法 |
| KR101770324B1 (ko) | 2016-11-09 | 2017-08-22 | 주식회사태준제약 | 안압 강하용 점안 조성물 |
| FR3064002B1 (fr) | 2017-03-14 | 2021-07-02 | Prevor Int | Melange liquide pour nettoyer les deversements de peinture, vernis, colorant et/ou lasure |
| CN114245737A (zh) | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| KR20220070246A (ko) | 2019-09-23 | 2022-05-30 | 디디에스 리서치 인크. | 침투 증진제를 갖는 지질 소포 조성물 |
| KR20230011997A (ko) * | 2020-05-13 | 2023-01-25 | 폴리클 파마 리미티드 | 모낭으로 생물활성제를 전달하기 위한 조성물 |
| EP3919047A1 (en) * | 2020-06-03 | 2021-12-08 | AZAD Pharma AG | Microemulsion for the treatment of dry eye syndrome |
| US20240058356A1 (en) * | 2020-12-24 | 2024-02-22 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition for transdermal administration containing epi-nastine or salt thereof and containing sulfur-based antioxidant |
| MX2023011157A (es) | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| ES2944784B8 (es) * | 2021-12-23 | 2026-04-21 | Univ Madrid Complutense | Microemulsión oftálmica, procedimiento de obtención y uso dado a la misma |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3608073A (en) | 1968-07-16 | 1971-09-21 | Barnes Hind Pharm Inc | Emulsion of pilocarpine for ophthalmic use |
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US5171566A (en) | 1986-05-16 | 1992-12-15 | The Green Cross Corporation | Flurbiprofen derivative ophthalmic preparation |
| JP2597629B2 (ja) | 1988-02-26 | 1997-04-09 | 株式会社 上野製薬応用研究所 | １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化 |
| CA2031469A1 (en) | 1989-12-28 | 1991-06-29 | Larry A. Wheeler | Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension |
| DE69105349T2 (de) | 1990-05-22 | 1995-04-06 | Ueno Seiyaku Oyo Kenkyujo Kk | Behandlung von intraocularem Druck mit einer synergistischen Kombination zur ophthalmischen Verwendung. |
| IL98747A0 (en) | 1991-07-05 | 1992-07-15 | Yissum Res Dev Co | Ophthalmic compositions |
| IL101241A (en) | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
| SE518823C2 (sv) | 1994-07-12 | 2002-11-26 | Karlshamns Lipidteknik Ab | Olja-i-vatten-emulsioner |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| US5827835A (en) | 1994-08-30 | 1998-10-27 | Alcon Laboratories, Inc. | Thermally-gelling emulsions |
| US6294563B1 (en) * | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
| US6770675B2 (en) | 1997-03-17 | 2004-08-03 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
| US6417228B1 (en) * | 1998-11-02 | 2002-07-09 | Alcon Manufacturing, Ltd.. | 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| CA2422031C (en) * | 2000-09-13 | 2011-11-15 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solutions comprising difluoroprostaglandin f2 alpha |
| US7095714B2 (en) | 2000-11-28 | 2006-08-22 | Kabushiki Kaisha Toshiba | Ring interconnection network system, node equipment, network management equipment, and path setting method |
| US20030215471A1 (en) | 2001-01-31 | 2003-11-20 | Wilmott James M. | Surfactant free topical compositions and method for rapid preparation thereof |
| WO2002096367A2 (en) * | 2001-05-30 | 2002-12-05 | Targesome, Inc. | Targeted multivalent macromolecules |
| KR100446960B1 (ko) * | 2001-12-04 | 2004-09-01 | 김종국 | 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물 |
| US20040076678A1 (en) | 2002-08-21 | 2004-04-22 | Sucampo Ag | Opthalmic solution |
| AU2003262268A1 (en) | 2002-08-23 | 2004-04-30 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
| CA2707067C (en) | 2002-09-09 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Clear ophthalmic solution comprising latanoprost as active ingredient |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
| US20050196370A1 (en) | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| WO2005011633A1 (ja) * | 2003-08-01 | 2005-02-10 | National Institute Of Advanced Industrial Science And Technology | 標的指向性リポソームを含む炎症性疾患治療薬または診断薬 |
| KR101091461B1 (ko) * | 2003-11-07 | 2011-12-07 | 센주 세이야꾸 가부시키가이샤 | 프로스타글란딘 함유 의약 조성물 |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| EP1655021B1 (en) | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
| KR101319772B1 (ko) | 2004-11-09 | 2013-10-23 | 노바갈리 파르마 에스 에이 | 면역 억제제를 포함하는 안과용 유제 |
| PT1937212E (pt) * | 2005-10-10 | 2010-11-30 | Novagali Pharma Sa | Emulsões oftálmicas contendo prostaglandinas |
| EP1985298A1 (en) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
-
2007
- 2007-04-24 EP EP07008357A patent/EP1985298A1/en not_active Withdrawn
-
2008
- 2008-04-24 JP JP2010504543A patent/JP5452472B2/ja active Active
- 2008-04-24 MX MX2009011391A patent/MX2009011391A/es active IP Right Grant
- 2008-04-24 CN CN2008800132624A patent/CN101674804B/zh active Active
- 2008-04-24 AU AU2008240964A patent/AU2008240964B2/en active Active
- 2008-04-24 WO PCT/EP2008/003317 patent/WO2008128779A1/en not_active Ceased
- 2008-04-24 NZ NZ579954A patent/NZ579954A/en unknown
- 2008-04-24 RU RU2009143324/15A patent/RU2460516C2/ru active
- 2008-04-24 US US12/597,528 patent/US8414904B2/en active Active
- 2008-04-24 CA CA2683672A patent/CA2683672C/en active Active
- 2008-04-24 EP EP08749111.4A patent/EP2136782B1/en active Active
- 2008-04-24 ES ES08749111T patent/ES2425593T3/es active Active
-
2013
- 2013-03-14 US US13/804,794 patent/US20130195936A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2460516C2 (ru) | 2012-09-10 |
| EP2136782B1 (en) | 2013-06-05 |
| CN101674804A (zh) | 2010-03-17 |
| JP2010524992A (ja) | 2010-07-22 |
| HK1133598A1 (en) | 2010-04-01 |
| EP2136782A1 (en) | 2009-12-30 |
| US20100112016A1 (en) | 2010-05-06 |
| MX2009011391A (es) | 2010-02-09 |
| US20130195936A1 (en) | 2013-08-01 |
| US8414904B2 (en) | 2013-04-09 |
| RU2009143324A (ru) | 2011-05-27 |
| CN101674804B (zh) | 2013-02-13 |
| WO2008128779A1 (en) | 2008-10-30 |
| AU2008240964A1 (en) | 2008-10-30 |
| CA2683672C (en) | 2015-10-06 |
| CA2683672A1 (en) | 2008-10-30 |
| EP1985298A1 (en) | 2008-10-29 |
| NZ579954A (en) | 2011-04-29 |
| JP5452472B2 (ja) | 2014-03-26 |
| AU2008240964B2 (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008240964B2 (en) | Ophthalmic oil-in-water emulsions containing prostaglandins | |
| RU2639472C2 (ru) | Офтальмическая композиция | |
| KR101510185B1 (ko) | 신규 안과용 조성물 | |
| US9089480B2 (en) | Anionic oil-in-water emulsions containing prostaglandins and uses thereof | |
| AU2013219822B2 (en) | Ophthalmic pharmaceutical compositions and methods of making and using same | |
| ES2453472T3 (es) | Emulsiones catiónicas de aceite en agua que contienen prostaglandinas y usos de estas | |
| KR20150000405A (ko) | 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법 | |
| KR20240031362A (ko) | 수성 겔 조성물 | |
| ES3012007T3 (en) | Lipid-based ophthalmic composition for the treatment of dry eye | |
| RU2841744C2 (ru) | Водная гелевая композиция | |
| HK1133598B (en) | Ophthalmic oil-in-water emulsions containing prostaglandins |